



# ALGORAE PHARMACEUTICALS

Algorae Pharmaceuticals Limited

ABN: 14 104 028 042

Level 23, Rialto South Tower

525 Collins Street

Melbourne, Victoria 3000

AUSTRALIA

Ph: +61 3 8689 9997,

Fax: + 61 3 9602 4709

Email: [info@lctglobal.com](mailto:info@lctglobal.com)

[www.algoraepharma.com](http://www.algoraepharma.com)

20 February 2024

Ms Lisa Banh  
Senior Adviser, Listings Compliance

By email: [ListingsComplianceSydney@asx.com.au](mailto:ListingsComplianceSydney@asx.com.au)

Dear Ms Banh,

## **Response to Algorae Pharmaceuticals Limited ('1AI'): Price - Query**

Algorae Pharmaceuticals Limited (ASX: **A1I**, the Company or Algorae) refers to your Price Query letter dated Tuesday 20 February 2024 and provides the following responses:

1. No.
2. Not applicable.
3. Algorae is aware of investor interest in biopharmaceutical companies engaged in the use of artificial intelligence for the discovery of drug candidates and their development.
4. The Company confirms that it is in compliance with the Listing Rules and, in particular, Listing Rule 3.1.
5. Algorae confirms that this response has been authorised and approved by the officer of 1AI with delegated authority from the Board to respond to ASX on disclosure matters.

Yours sincerely,

Leah Pieris  
Company Secretary



20 February 2024

Reference: 88908

Ms Leah Pieris  
Company Secretary  
Algorae Pharmaceuticals Limited

By email:

Dear Ms Pieris

### **Algorae Pharmaceuticals Limited ('1AI'): Price - Query**

ASX refers to the following:

- A. The change in the price of 1AI's securities from a low of \$0.01 to a high of \$0.012 today.
- B. The significant increase in the volume of 1AI's securities traded from 19 February 2024 to 20 February 2024.

### **Request for information**

In light of this, ASX asks 1AI to respond separately to each of the following questions and requests for information:

1. Is 1AI aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?
2. If the answer to question 1 is "yes".
  - (a) Is 1AI relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in 1AI's securities would suggest to ASX that such information may have ceased to be confidential and therefore 1AI may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.
  - (b) Can an announcement be made immediately? Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).
  - (c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?
3. If the answer to question 1 is "no", is there any other explanation that 1AI may have for the recent trading in its securities?
4. Please confirm that 1AI is complying with the Listing Rules and, in particular, Listing Rule 3.1.
5. Please confirm that 1AI's responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of 1AI with delegated authority from the board to respond to ASX on disclosure matters.

### **When and where to send your response**

This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than **4.30 PM AEDT Tuesday, 20 February 2024**. You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall

---

within the exceptions mentioned in Listing Rule 3.1A, 1AI's obligation is to disclose the information 'immediately'. This may require the information to be disclosed before the deadline set out in the previous paragraph and may require 1AI to request a trading halt immediately.

Your response should be sent to me by e-mail at **ListingsComplianceSydney@asx.com.au**. It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

### **Trading halt**

If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is "yes" and an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request a trading halt in 1AI's securities under Listing Rule 17.1. If you wish a trading halt, you must tell us:

- the reasons for the trading halt;
- how long you want the trading halt to last;
- the event you expect to happen that will end the trading halt;
- that you are not aware of any reason why the trading halt should not be granted; and
- any other information necessary to inform the market about the trading halt, or that we ask for.

We require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted. You can find further information about trading halts in Guidance Note 16 *Trading Halts & Voluntary Suspensions*.

### **Suspension**

If you are unable to respond to this letter by the time specified above, ASX will likely suspend trading in 1AI's securities under Listing Rule 17.3.

### **Listing Rules 3.1 and 3.1A**

In responding to this letter, you should have regard to 1AI's obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure*: Listing Rules 3.1 – 3.1B. It should be noted that 1AI's obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

### **Release of correspondence between ASX and entity**

ASX reserves the right to release all or any part of this letter, your reply and any other related correspondence between us to the market under Listing Rule 18.7A.

Kind regards

---

ASX Compliance